Obesity Awareness - twenty30 health

MASH Clash for Liver Disease; Google’s Verily Pivots to GLP-1 Meds; JPMorgan Chase $500M Bet on Weight-Loss Meds; MIT’s Bob Langer Launches NewCo; 40% Increase in Type 2 Diabetes in Young People

June 16, 2024 No Comments

AT A GLANCE STAT on Google’s health tech spinout Verily pivoting to offer GLP-1 drug prescriptions. MIT biotech legend Bob Langer and colleague Giovanni Traverso launched Syntis Bio, with a technology to coat the stomach, that impacts obesity. From Yahoo! Finance, JPMorgan Chase & Co.’s asset-management arm raised a $500 million fund to invest in weight-loss drugs. From Reuters, roughly one-third of US employer health plans are covering

Novo’s new Drug Development Partnership; Oprah on Making the Shift; No One Knows How to Talk About Weight Loss Anymore; One in Eight Adults in US have taken a GLP-1 Drug.

May 12, 2024 No Comments

AT A GLANCE Reuters states Novo Nordisk ties up with Metaphore from Flagship Pioneering to develop new obesity drugs. Oprah, in collaboration with Weightwatchers CEO Sima Sistani, joined by actress Rebel Wilson, as well as obesity experts this week. I am encouraged to read Jamie Ducharme’s article in TIME this week titled No One Knows How to Talk About Weight Loss Anymore – spot on! Betsy McKay

Medicare Coverage for GLP-1 meds; Oprah and Weight Stigma; Vast Underusage of Bariatric Surgery; Digital Diabetes Tools not Worth It; Obesity Costs in Pennsylvania at $20B.

March 24, 2024 No Comments

AT A GLANCE The Wall Street Journal’s Peter Loftus writes ‘…Medicare Opens Door for Covering Obesity Drugs.’ From Dani Blum at The New York Times, media icon Oprah Winfrey takes on weight stigma in her ABC News Special… starting with her own. Respected bariatric surgeon Dr. Bruce Schirmer, writes in JAMA Surgery on Metabolic Bariatric Surgery – A Vastly Underused Treatment. STAT reports digital tools for diabetes management

Anti-Obesity Meds for those with HIV; Medicare Approval Likely for Wegovy; Amazon Delivery of GLP-1 Meds; Obesity Treatment in Primary Care

March 17, 2024 No Comments

AT A GLANCE Nature journal reports ‘…People with HIV are the latest group to benefit from the new generation of anti-obesity drugs.’ STAT suggests FDA approval of Wegovy for heart benefits ‘…could provide a backdoor way to expand access to the drug for people on Medicare.’ Peter Loftus at The Wall Street Journal reveals those ‘…seeking a popular new weight-loss drug will have a new home-delivery option from

GLP-1 for Kidney Disease; FDA approves Wegovy for Cardiovascular Disease; Eli Lilly’s new Ad Campaign ahead of the Oscars; Obesity is South Africa’s New HIV Epidemic.

March 10, 2024 No Comments

AT A GLANCE Novo Nordisk’s FLOW trial of Ozempic demonstrates a ‘…24% reduction in the risk of kidney disease-related events…’ STAT reports on Novo Nordisk’s phase 1 trial of experimental oral medicine amycretin, with an average of 13.1% weight loss after 12 weeks. Reuters informs on Novo Nordisk market cap of $556 billion and had surpassed that of Tesla. The FDA approved ‘…a new indication for use

A Billion People Obese Worldwide; An Obesity Vaccine? – from Novo Nordisk and Vivani; Survodutide for Liver Disease; Bariatric Surgery Cures Diabetes

March 3, 2024 No Comments

AT A GLANCE STAT reports on Marcus Schindler, Novo’s chief scientific officer, who wants to ‘…make long-lasting GLP-1 molecules…’ with ‘…vaccine-like properties.’ NPM-115 and NPM-139 are miniature, subdermal GLP-1 implants from NASDAQ-listed company Vivani Medical, Inc. that provide once- or twice-yearly administration. STAT reports from a study in The Lancet that ‘…more than 1 billion people – or one in eight people worldwide –

Ro Prescribes Compounded Semaglutide; Tirzetapide for Fatty Liver; Obesity Center of Excellence; No-Zempic; AMG133 and Survodutide.

February 11, 2024 No Comments

AT A GLANCE STAT reports on Eli Lilly drug trial of tirzetapide as a treatment for the liver disease MASH. Business Insider reporter Shelby Livingston notes ‘…startup Ro just started prescribing “compounded” semaglutide, an alternative to Ozempic.’ Milliman, an international actuarial and consulting firm based in Seattle, Washington, explores the concept of an obesity center of excellence. No-zempic is leaving lots of people behind, from

LillyDirect for Zepbound; Novo bets on mRNA Drug for Obesity; WW, Noom and Ro run the ‘Obesity Games’ gauntlet; Weight Loss and Work Success.

January 7, 2024 No Comments

AT A GLANCE Eli Lilly launches LillyDirect Pharmacy Solutions, with an independent, virtual medical weight-loss clinic, to provide direct consumer access to Zepbound. Novo Nordisk is working with Omega Therapeutics, a start-up from the same stable as moderna, ‘…to develop an mRNA treatment for obesity…’ from STAT News. Rebecca Torrence at Business Insider notes ‘…only a handful of companies have what it takes to make

NIH reviews Obesity in Kids; Altimmune and Pfizer report on new Obesity Drug Trials; Novo CEO wants Shared Risk Pricing for Wegovy; Ozempic vs. Mounjaro – let the Head-to-Head games begin.

December 3, 2023 No Comments

AT A GLANCE The National Institute of Health, or the NIH, held a two-day meeting this week on pharmacotherapy for obesity in children and adolescents. Pfizer announced data for their in-house GLP-1 agonist drug danuglipron, with ‘…mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks…’ Altimmune announced ‘…results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide…’, with mean weight losses of up to 15.6%, and 30%

Access to anti-obesity medications for Black Americans; Thanksgiving and the weight loss conversation; a four-monthly GLP-1 shot.

November 26, 2023 No Comments

AT A GLANCE Atiya Jordan recounts in Black Enterprise the disparity ‘…between the use of the anti-obesity and diabetes medication among Black people…’ while ‘…white people are four times more likely to receive a prescription.’ A new Tema Cardiovascular & Metabolic ETF, or exchange traded fund, seeks to invest ‘…in companies tackling diabetes, obesity and cardiovascular diseases…’ from Bansari Mayur Kamdar at Reuters. Alex Janin writes in

Category: Obesity Awareness